Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

ACC 2024 Congress

Catch up on all the top stories and latest evidence in cardiology research with our ACC 2024 Congress hub page.
ADVANCED SEARCH
Log in
Top
European Journal of Clinical Microbiology & Infectious Diseases
Published in: European Journal of Clinical Microbiology & Infectious Diseases 11/2020

01-11-2020 | Vancomycin | Brief Report

A comparison of daptomycin alone and in combination with ceftaroline fosamil for methicillin-resistant Staphylococcus aureus bacteremia complicated by septic pulmonary emboli

Authors: Taylor Morrisette, Abdalhamid M. Lagnf, Sara Alosaimy, Michael J. Rybak

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 11/2020

Login to get access

Abstract

The use of daptomycin (DAP) in septic pulmonary emboli (SPE) remains controversial. We analyzed 29 cases of MRSA bacteremia complicated by SPE treated with DAP (n = 14) or DAP-ceftaroline fosamil (CPT; n = 15). Initial treatment with DAP monotherapy was found to have a success rate comparable with DAP-CPT (71% vs. 80%; p = 0.68).
Literature
1.
2.
van Hal SJ, Fowler VG Jr (2013) Is it time to replace vancomycin in the treatment of methicillin-resistant Staphylococcus aureus infections? Clin Infect Dis 56:1779–1788CrossRef
3.
Goswami U, Brenes JA, Punjabi GV, LeClaire MM, Williams DN (2014) Associations and outcomes of septic pulmonary emboli. Open Respir Med J 8:28–33CrossRef
4.
Silverman JA, Mortin LE, VanPraagh ADG, Li T, Alder J (2005) Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J Infect Dis 191:2149–2152CrossRef
5.
Crass RL, Powell KL, Huang AM (2019) Daptomycin for the treatment of Staphylococcus aureus infections complicated by septic pulmonary emboli. Diagn Microbiol Infect Dis 93:131–135CrossRef
6.
Wong D, Chandraratna AN, Wishnow RM, Dusitnanond V, Nimalasuriya A (1983) Clinical implications of large vegetations in infectious endocarditis. Arch Intern Med 143:1874–1877CrossRef
7.
Rehm SJ, Boucher H, Levine D et al (2008) Daptomycin versus vancomycin plus gentamicin for treatment of bacteraemia and endocarditis due to Staphylococcus aureus: subset analysis of patients infected with methicillin-resistant isolates. J Antimicrob Chemother 62:1413–1421CrossRef
8.
Kanafani Z, Boucher H, Fowler V et al (2010) Daptomycin compared to standard therapy for the treatment of native valve endocarditis. Enferm Infecc Microbiol Clin 28:498–503CrossRef
9.
Werth BJ, Sakoulas G, Rose WE, Pgliano J, Tewhey R, Rybak MJ (2013) Ceftaroline increases membrane binding and enhances the activity of daptomycin against daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus in a pharmacokinetic/pharmacodynamics model. Antimicrob Agents Chemother 57:66–73CrossRef
10.
Geriak M, Haddad F, Rizvi K et al (2019) Clinical data on daptomycin plus ceftaroline versus standard of care monotherapy in the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 63. https://​doi.​org/​10.​1128/​AAC.​02483-18
11.
Fowler VG Jr, Boucher HW, Corey GR et al (2006) Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 355:653–665CrossRef
12.
Harada Y, Yanagihara K, Yamada K et al (2013) In vivo efficacy of daptomycin against methicillin-resistant Staphylococcus aureus in a mouse model of hematogenous pulmonary infection. Antimicrob Agents Chemother 57:2841–2844CrossRef
13.
Kephart PA, Esposito AL (1988) Comparison of the investigational drug, LY146032, with vancomycin in experimental pneumonia due to methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 21:33–39CrossRef
14.
Verghese A, Haire C, Franzus B, Smith K (1988) LY146032 in a hamster model of Staphylococcus aureus pneumonia—effect on in vivo clearance and mortality and in vitro opsonophagocytic killing. Chemotherapy 34:497–503CrossRef
15.
Heine HS, Basset J, Miller L, Purcell BK, Byrne WR (2010) Efficacy of daptomycin against Bacillus anthracis in a murine model of anthrax spore inhalation. Antimicrob Agents Chemother 54:4471–4473CrossRef
16.
Pertel PE, Bernardo P, Fogarty C et al (2008) Effects of prior effective therapy on the efficacy on daptomycin and ceftriaxone for the treatment of community-acquired pneumonia. Clin Infect Dis 46:1142–1151CrossRef
17.
Hagiya H, Hagioka S, Otsuka F (2013) Ineffectiveness of daptomycin in the treatment of septic pulmonary emboli and persistent bacteremia caused by methicillin-resistant Staphylococcus aureus. Intern Med 52:2577–2582CrossRef
Metadata
Title
A comparison of daptomycin alone and in combination with ceftaroline fosamil for methicillin-resistant Staphylococcus aureus bacteremia complicated by septic pulmonary emboli
Authors
Taylor Morrisette
Abdalhamid M. Lagnf
Sara Alosaimy
Michael J. Rybak
Publication date
01-11-2020
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Clinical Microbiology & Infectious Diseases / Issue 11/2020
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-020-03941-5

Other articles of this Issue 11/2020

European Journal of Clinical Microbiology & Infectious Diseases 11/2020 Go to the issue

Brief Report

Evaluation of rapid polymyxin Nordmann Poirel test for detection of polymyxin resistance in clinical isolates of Enterobacteriaceae

Original Article

Complement levels in patients with bloodstream infection due to Staphylococcus aureus or Gram-negative bacteria

Original Article

Analysis of predisposing factors for the development of Clostridioides difficile infection recurrence

Original Article

Antimicrobial resistance, genetic characterization, and molecular epidemiology of Ureaplasma species in males with infertility

Original Article

Management and outcomes of Burkholderia cepacia complex bacteremia in patients without cystic fibrosis: a retrospective observational study

Original Article

Diagnostic parameters of modified two-tier testing in European patients with early Lyme disease

ACC 2024 Congress Coverage

Cardiology Video

Highlights from the ACC 2024 Congress

Watch now

Watch official videos from the ACC congress summarizing key highlights from the last year in heart failure, cardiomyopathies, valvular disease, pulmonary vascular disease, and pediatric cardiology.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits